Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58.

Article  CAS  PubMed  Google Scholar 

Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015;28(5):508–15.

Article  PubMed  Google Scholar 

Kiang TK, Ensom MH. Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update. Expert Opin Drug Metab Toxicol. 2016;12(5):545–53.

Article  CAS  PubMed  Google Scholar 

Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet. 2018;57(5):547–58.

Article  CAS  PubMed  Google Scholar 

Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N. Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: review of the evidence and clinical implications. J Clin Pharmacol. 2020;60(3):295–311.

Article  CAS  PubMed  Google Scholar 

Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2021;43(2):150–200.

Article  CAS  PubMed  Google Scholar 

Rong Y, Jun H, Kiang TKL. Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol. 2021;87(4):1730–57.

Article  CAS  PubMed  Google Scholar 

Rong Y, Patel V, Kiang TKL. Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects. Expert Opin Drug Metab Toxicol. 2022;17(12):1369–406.

Article  Google Scholar 

Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33(1):139–46.

Article  CAS  PubMed  Google Scholar 

Uwai Y, Motohashi H, Tsuji Y, Ueo H, Katsura T, Inui K. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007;74(1):161–8.

Article  CAS  PubMed  Google Scholar 

El-Sheikh AA, Koenderink JB, Wouterse AC, van den Broek PH, Verweij VG, Masereeuw R, et al. Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. Transl Res. 2014;164(1):46–56.

Article  CAS  PubMed  Google Scholar 

Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther. 2010;87(1):100–8.

Article  CAS  PubMed  Google Scholar 

Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307.

Article  CAS  PubMed  Google Scholar 

Rong Y, Colbourne P, Gourishankar S, Kiang TKL. Significant correlations between p-cresol sulfate and mycophenolic acid plasma concentrations in adult kidney transplant recipients. Clin Drug Investig. 2022;42(3):207–19.

Article  CAS  PubMed  Google Scholar 

Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88(7):1351–89.

Article  CAS  PubMed  Google Scholar 

Kiang TKL, Ensom MHH. Exposure-toxicity relationships of mycophenolic acid in adult kidney transplant patients. Clin Pharmacokinet. 2019;58(12):1533–52.

Article  CAS  PubMed  Google Scholar 

Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64(6):672–83.

Article  CAS  PubMed  Google Scholar 

Greanya ED, Poulin E, Partovi N, Shapiro RJ, Al-Khatib M, Ensom MH. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. Am J Health Syst Pharm. 2012;69(2):134–42.

Article  CAS  PubMed  Google Scholar 

Wang P, Xie H, Zhang Q, Tian X, Feng Y, Qin Z, et al. Population pharmacokinetics of mycophenolic acid in renal transplant patients: a comparison of the early and stable posttransplant stages. Front Pharmacol. 2022;13: 859351.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17(3):871–80.

Article  PubMed  Google Scholar 

van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63(6):741–52.

Article  PubMed  PubMed Central  Google Scholar 

Nourbakhsh N, Ekberg J, Skov K, Peters CD, Ozbay A, Lindner P, et al. Effects of corticosteroid treatment on mycophenolic acid exposure in renal transplant patients-results from the SAILOR study. Front Pharmacol. 2021;12: 742444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62(3):1060–7.

Article  CAS  PubMed  Google Scholar 

Kiang TK, Ensom MH. Anti-rejection drugs. In: Murphy JE, editor. Clinical pharmacokinetics (6th Edition). Bethesda: American Society of Health-System Pharmacists; 2017. p. 205–20.

Google Scholar 

Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet. 2012;51(11):711–41.

Article  CAS  PubMed  Google Scholar 

Steiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol. 2011;33(2):157–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Lucena DD, Rangel EB. Glucocorticoids use in kidney transplant setting. Expert Opin Drug Metab Toxicol. 2018;14(10):1023–41.

Article  PubMed  Google Scholar 

Wishart GJ, Dutton GJ. Regulation of onset of development of UDP-glucuronosyltransferase activity towards o-aminophenol by glucocorticoids in late-foetal rat liver in utero. Biochem J. 1977;168(3):507–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuetz EG, Hazelton GA, Hall J, Watkins PB, Klaassen CD, Guzelian PS. Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem. 1986;261(18):8270–5.

Article  CAS  PubMed  Google Scholar 

Kanou M, Usui T, Ueyama H, Sato H, Ohkubo I, Mizutani T. Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone. Mol Biol Rep. 2004;31(3):151–8.

Article  CAS  PubMed  Google Scholar 

Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos. 2004;32(1):140–8.

Article  CAS  PubMed  Google Scholar 

Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics. 2007;17(5):321–30.

Article  CAS  PubMed  Google Scholar 

Qadri I, Hu LJ, Iwahashi M, Al-Zuabi S, Quattrochi LC, Simon FR. Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2). Toxicol Appl Pharmacol. 2009;234(3):281–92.

Article  CAS  PubMed  Google Scholar 

Rosales R, Romero MR, Vaquero J, Monte MJ, Requena P, Martinez-Augustin O, et al. FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver. Biochem Pharmacol. 2013;85(6):829–38.

Article  CAS  PubMed  Google Scholar 

Wang H, Liu C, You G. The activity of organic anion transporter-3: role of dexamethasone. J Pharmacol Sci. 2018;136(2):79–85.